BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 30, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Infection

Enanta Pharmaceuticals patents SARS-CoV-2 Mpro inhibitors

June 6, 2023
Several recent Enanta Pharmaceuticals Inc...
Read More

Sea-Long Medical says FDA inspection ‘a good learning experience’

June 2, 2023
By Mark McCarty
U.S. FDA inspections are not always a pleasant experience, particularly when the end result is a warning letter. One company, Sea-Long Medical Systems LLC of Waxahachie, Texas, says the experience was a positive experience in that the company’s new ownership gained an important appreciation for the necessary rigors of medical device manufacturing.
Read More

Regulatory actions for June 1, 2023

June 1, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acticor, Aridis, Ascentage, Cocrystal, IGM, Pepgen, Pharmazz, Precigen, Rocket.
Read More
Infection

Insilico Medicine divulges new 3CLpro inhibitors for SARS-CoV-2

June 1, 2023
Insilico Medicine IP Ltd. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Read More
Coronavirus variants
Infection

New approach for SARS-CoV-2 immunoprophylaxis through receptor decoys

June 1, 2023
Researchers from NYU Grossman School of Medicine reported on a new strategy intended to provide long-term protection against the SARS-CoV-2 virus using an experimental decoy.
Read More

Regulatory actions for May 31, 2023

May 31, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akebia, Amylyx, Beigene, Bristol Myers Squibb, Inhibrx, Iovance, Janssen, Lexicon, Metriopharm, SK, Valneva.
Read More

In the clinic for May 31, 2023

May 31, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: A2, Abbisko, Algiax, Alterity, Alzecure, Aum, Consynance, Debiopharm, Dermbiont, Fore, Genprex, Hansa, Harbour, Immorna, Luzhu, Pfizer, Pyxis, Revive, Selection, Springworks, Theratechnologies.
Read More

Other news to note for May 31, 2023

May 31, 2023
Additional early-stage research and drug discovery news in brief, from: Amplia Therapeutics, Can-Fite Biopharma, Imunon, Lixte Biotechnology, Regcell.
Read More
Illustration of coronavirus blocked by the no symbol
Infection

Novel nonpeptidic SARS-CoV-2 3CLpro inhibitor demonstrates good antiviral activity

May 31, 2023
In the effort to tackle the recent global SARS-CoV-2 pandemic, multiple peptide-like covalent SARS...
Read More
COVID-19 vaccine and syringe with flag of China

Cansino steps closer to COVID-19 mRNA vaccine approval in China

May 30, 2023
By Doris Yu
Cansino Biologics Inc. reported positive data in a phase IIb trial evaluating the heterologous mRNA vaccine CS-2034 booster compared to an inactivated vaccine to prevent SARS-CoV-2 infections.
Read More
Previous 1 2 … 39 40 41 42 43 44 45 46 47 … 553 554 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2026.
  • Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

    ENCALS 2026: From genetics to advancing strategies against ALS

    BioWorld Science
    Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 30, 2026
  • Handshake with DNA, molecules

    Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement

    BioWorld Science
    Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
  • Digital brain with dollar sign

    Investors bet on transformative BCI tech for neuro disorders

    BioWorld
    An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing